import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "how-much-does-orforglipron-cost-research-pricing-guide",
  title: "How Much Does Orforglipron Cost? Oral GLP-1 Small Molecule Research Pricing (2026)",
  description:
    "Orforglipron research compound pricing in 2026 — cost benchmarks for this oral non-peptide GLP-1 receptor agonist, how it differs from injectable GLP-1 analogs in sourcing, and what researchers should verify before procurement.",
  category: "Sourcing & Pricing",
  readMinutes: 6,
  publishedAt: "2026-06-18",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Orforglipron (LY3502970) is a non-peptide oral GLP-1 receptor agonist developed by Eli Lilly that has attracted significant research attention in 2025–2026 as a potentially first-in-class oral small molecule alternative to injectable semaglutide and tirzepatide. Unlike peptide-based GLP-1 agonists, orforglipron is a small organic molecule — meaning it does not require reconstitution, does not degrade through peptide hydrolysis pathways, and is absorbed orally without the pharmaceutical tricks (fatty acid conjugation, absorption enhancers) that oral semaglutide requires. This changes the research procurement and pricing landscape substantially relative to injectable GLP-1 peptide analogs.",
    },
    {
      type: "heading",
      text: "Orforglipron: Small Molecule, Not a Peptide",
    },
    {
      type: "paragraph",
      text: "A critical distinction for researchers: orforglipron is a small molecule GLP-1 receptor agonist, not a peptide. Its molecular weight is approximately 530 Da (compared to semaglutide at ~4,114 Da or tirzepatide at ~4,813 Da). This means the procurement, handling, analytical verification, and pricing framework differs from the standard research peptide market. Orforglipron sourcing follows small molecule research chemical conventions rather than peptide conventions.",
    },
    {
      type: "heading",
      text: "Orforglipron Research Compound Pricing: Market Overview",
    },
    {
      type: "paragraph",
      text: "As of mid-2026, research-grade orforglipron from suppliers with documented HPLC purity and NMR or LC-MS confirmation typically ranges from $8.00 to $25.00 per mg for analytical-grade material. Bulk quantities for in vivo rodent metabolic studies may be available at lower per-mg rates. Pricing is influenced heavily by synthesis route complexity and supplier specialization in GLP-1 small molecule research tools.",
    },
    {
      type: "table",
      headers: ["Quantity", "Typical Price Range (Quality Supplier)", "Price Per mg"],
      rows: [
        ["5 mg", "$55–$150", "$11.00–$30.00/mg"],
        ["10 mg", "$90–$220", "$9.00–$22.00/mg"],
        ["25 mg", "$175–$425", "$7.00–$17.00/mg"],
        ["50 mg", "$300–$700", "$6.00–$14.00/mg"],
        ["100 mg (in vivo bulk)", "$500–$1,200", "$5.00–$12.00/mg"],
      ],
    },
    {
      type: "callout",
      text: "Orforglipron sourced below $5/mg warrants careful identity verification. GLP-1 small molecule agonists have complex synthetic pathways; impure batches or structurally similar analogs may show similar HPLC profiles but differ in receptor pharmacology. LC-MS/MS or NMR confirmation is essential.",
    },
    {
      type: "heading",
      text: "How Orforglipron Pricing Compares to Injectable GLP-1 Peptides",
    },
    {
      type: "paragraph",
      text: "The per-mg cost of orforglipron is higher than injectable GLP-1 peptide analogs like semaglutide or liraglutide, but this comparison is somewhat misleading for study design purposes. Because orforglipron is a small molecule with oral bioavailability in rodent models, its per-animal dose in mg/kg may be administered orally via gavage without the reconstitution infrastructure, cold-chain injection logistics, and subcutaneous injection technique variability of peptide comparators.",
    },
    {
      type: "table",
      headers: ["Compound", "Typical Research Price/mg (2026)", "Route", "Key Difference"],
      rows: [
        ["Orforglipron", "$6–$22/mg", "Oral (small molecule)", "No reconstitution; oral bioavailability; stable at room temp"],
        ["Semaglutide analog", "$3–$8/mg", "SC injection", "Peptide; cold-chain; requires reconstitution; fatty acid modified"],
        ["Tirzepatide analog", "$3–$9/mg", "SC injection", "Dual agonist peptide; complex synthesis; cold-chain required"],
        ["Liraglutide analog", "$2–$6/mg", "SC injection", "Daily injection model; lower per-mg cost; established market"],
      ],
    },
    {
      type: "heading",
      text: "What Drives Orforglipron Price Variation?",
    },
    {
      type: "subheading",
      text: "Synthetic Complexity",
    },
    {
      type: "paragraph",
      text: "Orforglipron is a pyrrolidine-based oral non-peptide GLP-1 agonist with a complex chiral synthesis pathway. Total synthesis requires multiple steps with stereospecific transformations — synthetic errors at any step can produce diastereomers with different receptor potencies. Unlike peptides where amino acid sequence verification confirms identity straightforwardly, small molecule synthesis errors require more sophisticated structural elucidation tools (NMR, HRMS) to detect.",
    },
    {
      type: "subheading",
      text: "Analytical Verification Standards",
    },
    {
      type: "paragraph",
      text: "For a research-grade small molecule GLP-1 agonist, quality documentation should include: ¹H NMR or ¹H/¹³C NMR for structural confirmation, high-resolution mass spectrometry (HRMS) for exact molecular formula confirmation, HPLC chromatogram ≥98% purity (typically by UV at 254 nm), and optical rotation or chiral HPLC if stereochemistry is specified. Suppliers offering only standard HPLC without structural NMR or HRMS provide insufficient documentation for pharmacology research.",
    },
    {
      type: "subheading",
      text: "Supply Chain Maturity",
    },
    {
      type: "paragraph",
      text: "Orforglipron is still in clinical development as of 2026, meaning fewer research chemical suppliers have invested in optimizing its synthesis at research scale. Limited supplier competition keeps per-mg prices elevated compared to established peptides with mature supply chains. As clinical development progresses and research demand grows, pricing is expected to decrease following the pattern established by tirzepatide (2022–2024) and semaglutide (2021–2023) in the research market.",
    },
    {
      type: "heading",
      text: "Storage and Handling: Advantages Over Peptide GLP-1 Analogs",
    },
    {
      type: "paragraph",
      text: "One practical advantage of orforglipron for research operations: small molecule stability. Unlike fatty-acid-modified GLP-1 peptides requiring strict cold chain, orforglipron as a small organic molecule is substantially more stable:",
    },
    {
      type: "list",
      items: [
        "Stable as solid at room temperature (15–25°C) in a desiccated container, short term",
        "Long-term storage at -20°C recommended in sealed, desiccated containers",
        "Soluble in DMSO for stock solution preparation; dilute in PBS/vehicle for in vivo use (minimize DMSO concentration in final dose)",
        "No reconstitution from lyophilized peptide required; weigh directly for solution preparation",
        "No freeze-thaw degradation risk comparable to disulfide-containing or fatty-acid-modified peptides",
      ],
    },
    {
      type: "heading",
      text: "In Vivo Research Budget Planning for Orforglipron",
    },
    {
      type: "paragraph",
      text: "For rodent metabolic studies using orforglipron, typical research doses in mouse models have been used at 1–10 mg/kg orally. Planning a diet-induced obesity (DIO) mouse study with 20 animals over 4 weeks at 3 mg/kg once daily:",
    },
    {
      type: "list",
      items: [
        "Average mouse weight: ~35g (DIO model)",
        "Daily dose per mouse: 35g × 3mg/kg = 0.105 mg/mouse",
        "Total for 20 mice over 28 days: 0.105 × 20 × 28 = 58.8 mg",
        "With 20% buffer for prep waste: ~70–75 mg total",
        "Estimated cost at $7/mg: ~$490–$525 for peptide material alone",
        "Add vehicle, analytics, and shipping costs on top",
      ],
    },
    {
      type: "heading",
      text: "Documentation Checklist for Orforglipron Research Procurement",
    },
    {
      type: "list",
      items: [
        "HPLC chromatogram: ≥98% purity at UV 254 nm, batch-specific with integration report",
        "High-resolution mass spectrometry (HRMS): exact mass matching orforglipron molecular formula [C₂₄H₂₈F₃N₅O₂, MW 503.51]",
        "¹H NMR spectrum: structural confirmation matching published chemical shift data",
        "Chiral purity documentation if available: orforglipron has stereocenters; confirm correct enantiomer",
        "Certificate of Analysis (COA): lot number, date of analysis, identity summary",
        "Country of synthesis and GMP/research-grade manufacturing standard",
      ],
    },
    {
      type: "heading",
      text: "Nexphoria Orforglipron Availability",
    },
    {
      type: "paragraph",
      text: "Nexphoria offers orforglipron research compound with batch-specific HPLC chromatograms, LC-MS identity confirmation, and COA documentation. For high-quantity in vivo study procurement, contact the research team for bulk pricing. Current pricing and available quantities are listed on the Orforglipron product page.",
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "Research-grade orforglipron costs $6–$22 per mg in 2026, reflecting its complex synthesis pathway and limited research market supply chain relative to established GLP-1 peptide analogs. Its small molecule nature simplifies storage and handling compared to injectable GLP-1 peptides but demands more rigorous structural analytical documentation (NMR + HRMS rather than MS alone). Researchers planning dose-response or metabolic model studies should budget $500–$1,000+ in compound costs for a full rodent cohort study at typical in vivo doses.",
    },
    {
      type: "disclaimer",
      text: "Orforglipron is offered by Nexphoria exclusively for in vitro and preclinical research purposes. It is not intended for human consumption, therapeutic use, or diagnostic application. This compound is under active clinical development; Nexphoria's research-grade material is an analog for mechanistic research only.",
    },
  ],
};
